Intravenous injection of bovine serum albumin (BSA) into the BSA/CFA-primed ICR mice specifically induced anaphylactic death within 1 h. The anaphylactic death could not be induced until day 8 after sensitization, and sensitization subsisted for more than 3 months. The response was dose dependent; mice challenged with BSA doses higher or equivalent to 25 μg developed anaphylactic death. The intravenous route was more effective than the intraperitoneal one, while subcutaneous injection was ineffective. Antigen in any of complete Freund’s adjuvant, incomplete Freund’s adjuvant or aluminum hydroxide could sensitize the mice to develop anaphylactic death. The combination of antigen and the mouse strain or the gender of the mouse determined the susceptibility of the anaphylactic death. AKR, B10.BR, as well as ICR, strains were susceptible. Antigen of HoGG induced a higher mortality rate than that of GAT or lysozyme. Male mice were more susceptible than female ones. The BSA-induced anaphylactic death could be prevented by pretreating ICR mice with cyproheptadine (histamine and serotonin antagonist) or diphenhydramine (histamine antagonist) and ketanserin (serotonin antagonist). Intravenous injection of saline during anaphylaxis also protected the mice from death. Furthermore, immune serum could transfer the anaphylactic death, and heat (56°C, 4 h) did not destroy its activity. The primary IgG subclass induced by GAT, HoGG or lysozyme was IgGl. There was no qualitative difference in the IgG subclass induced in different strains by different antigens. The IgE class of antibodies was not detectable. These results suggest that there is a non-IgE-mediated anaphylactic death which involves the release of histamine and serotonin that cause the increase of vasopermeability and fatal blood volume loss.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.